MWNA
ACHN

Marshall Wace North America’s Achillion Pharmaceuticals ACHN Stock Holding History

Marshall Wace North America’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-820,146
Closed -$3.02M – 1735
2018
Q3 		$3.02M Buy
820,146
+674,956
+465% +$2.01M 0.02% 412
2018
Q2 		$411K Buy
+145,190
New +$495K ﹤0.01% 1121
2018
Q1 		– Sell
-558,105
Closed -$1.61M – 1822
2017
Q4 		$1.61M Buy
+558,105
New +$2.03M 0.01% 894

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Marshall Wace North America's ACHN Position: Q4 2018 in Review

Marshall Wace North America sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 820,146 shares — an estimated $3.02M sold.

Marshall Wace North America first reported a position in ACHN in Q4 2017 and held it in 3 quarters. The position peaked at $3.02M in Q3 2018. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

  • Marshall Wace North America reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace North America sold 820,146 Achillion Pharmaceuticals shares in Q4 2018, an estimated $3.02M.
  • Marshall Wace North America first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Marshall Wace North America's Achillion Pharmaceuticals position peaked at $3.02M in Q3 2018.
  • 121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on Marshall Wace North America's 13F filing for Q4 2018, filed 14 Feb 2019.